S. van Doorn

First name
S.
Last name
van Doorn
Hunt, N. B., Pajouheshnia, R. ., Salih, A. ., van Doorn, S. ., Souverein, P. C., Bazelier, M. T., … Gardarsdottir, H. . (2023). Prescribing of Low-dose Rivaroxaban in Patients with Atherosclerotic Cardiovascular Disease in the United Kingdom and the Netherlands. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15708
van den Dries, C. J., Pajouheshnia, R. ., van den Ham, H. A., Souverein, P. ., Moons, K. G. M., Hoes, A. W., … van Doorn, S. . (2022). Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15534
van den Dries, C. J., van Doorn, S. ., Souverein, P. ., Pajouheshnia, R. ., Moons, K. G. M., Hoes, A. W., … van den Ham, H. A. (2020). The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation. TH Open. http://doi.org/10.1055/s-0040-1721499